583 related articles for article (PubMed ID: 25640470)
1. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis.
Voskamp AL; Gillman A; Symons K; Sandrini A; Rolland JM; O'Hehir RE; Douglass JA
J Allergy Clin Immunol Pract; 2015; 3(2):192-9. PubMed ID: 25640470
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature.
Li JX; Fan LC; Li MH; Cao WJ; Xu JF
Respir Med; 2017 Jan; 122():33-42. PubMed ID: 27993289
[TBL] [Abstract][Full Text] [Related]
3. Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab.
Lin RY; Sethi S; Bhargave GA
J Asthma; 2010 Oct; 47(8):942-5. PubMed ID: 20831464
[TBL] [Abstract][Full Text] [Related]
4. Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis.
Zicari AM; Celani C; De Castro G; Valerio De Biase R; Duse M
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1839-41. PubMed ID: 25010610
[TBL] [Abstract][Full Text] [Related]
5. Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients.
Nové-Josserand R; Grard S; Auzou L; Reix P; Murris-Espin M; Brémont F; Mammar B; Mely L; Hubert D; Durieu I; Burgel PR
Pediatr Pulmonol; 2017 Feb; 52(2):190-197. PubMed ID: 27717223
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases.
Aydın Ö; Sözener ZÇ; Soyyiğit Ş; Kendirlinan R; Gençtürk Z; Mısırlıgil Z; Mungan D; Sin BA; Demirel YS; Çelik GE; Bavbek S
Allergy Asthma Proc; 2015; 36(6):493-500. PubMed ID: 26534756
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis.
Perisson C; Destruys L; Grenet D; Bassinet L; Derelle J; Sermet-Gaudelus I; Thumerelle C; Prevotat A; Rosner V; Clement A; Corvol H
Respir Med; 2017 Dec; 133():12-15. PubMed ID: 29173443
[TBL] [Abstract][Full Text] [Related]
8. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
Jat KR; Walia DK; Khairwa A
Cochrane Database Syst Rev; 2015 Nov; (11):CD010288. PubMed ID: 26545165
[TBL] [Abstract][Full Text] [Related]
9. Anti-IgE therapy for allergic bronchopulmonary aspergillosis.
Homma T; Kurokawa M; Matsukura S; Yamaguchi M; Adachi M
J Microbiol Immunol Infect; 2016 Jun; 49(3):459-63. PubMed ID: 24291616
[TBL] [Abstract][Full Text] [Related]
10. Molecular-based allergy diagnosis of allergic bronchopulmonary aspergillosis in Aspergillus fumigatus-sensitized Japanese patients.
Tanimoto H; Fukutomi Y; Yasueda H; Takeuchi Y; Saito A; Watai K; Sekiya K; Tsuburai T; Asano K; Taniguchi M; Akiyama K
Clin Exp Allergy; 2015 Dec; 45(12):1790-800. PubMed ID: 26118958
[TBL] [Abstract][Full Text] [Related]
11. Unexpected decrease in total IgE in a patient with allergic bronchopulmonary aspergillosis treated with omalizumab.
Wolf BL; Johnson A
J Allergy Clin Immunol Pract; 2014; 2(1):111-3. PubMed ID: 24565782
[No Abstract] [Full Text] [Related]
12. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
Jat KR; Walia DK; Khairwa A
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD010288. PubMed ID: 29551015
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis.
Evans MO; Morris MJ; Coop CA; Evans SE
Ann Allergy Asthma Immunol; 2015 Sep; 115(3):250-1. PubMed ID: 26162570
[No Abstract] [Full Text] [Related]
14. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
Jat KR; Walia DK; Khairwa A
Cochrane Database Syst Rev; 2013 Sep; (9):CD010288. PubMed ID: 24043500
[TBL] [Abstract][Full Text] [Related]
15. Utility of IgE (total and Aspergillus fumigatus specific) in monitoring for response and exacerbations in allergic bronchopulmonary aspergillosis.
Agarwal R; Aggarwal AN; Sehgal IS; Dhooria S; Behera D; Chakrabarti A
Mycoses; 2016 Jan; 59(1):1-6. PubMed ID: 26575791
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
17. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
18. Time course of antibody response to recombinant Aspergillus fumigatus antigens in cystic fibrosis with and without ABPA.
Casaulta C; Flückiger S; Crameri R; Blaser K; Schoeni MH
Pediatr Allergy Immunol; 2005 May; 16(3):217-25. PubMed ID: 15853950
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic autoimmune urticaria with omalizumab.
Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
[TBL] [Abstract][Full Text] [Related]
20. Serologic allergic bronchopulmonary aspergillosis (ABPA-S): long-term outcomes.
Agarwal R; Garg M; Aggarwal AN; Saikia B; Gupta D; Chakrabarti A
Respir Med; 2012 Jul; 106(7):942-7. PubMed ID: 22445696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
